Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use Open-Label Study of Anti-IL-5 (Mepolizumab) in Life-Threatening Hypereosinophilic Syndrome
2007-000838-39Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mepolizumab in hypereosinophilic syndrome (HES), sponsored by GSK. Primary endpoint: Primary safety and effectiveness of long-term mepolizumab exposure. Started Apr 2007; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2007-000838-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000838-39.